Dr Reddy's Laboratories received 483 observations for its unit 6 of Vizag plant. The Vizag plant, which manufactures active pharmaceutical ingredient (API) and bulk drugs, was visited by the US Food and Drug Administration last week.

Commenting on the same, Sarabjit Kour Nangra, VP - Research Pharma, Angel Broking, said, "483 observations received are unlikely to affect the production of the company and therefore, it will continue as per normal routine. We maintain our neutral stance on the stock."

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.